Latebreaker Trial Shows Heart Failure Recovery Is Remission and Not a Cure

Treatment Options on the Horizon for Glaucoma Management

Psoriatic Arthritis Remains Controlled on Anti-IL-17 Agents out to Three Years

CANTOS Trial Advances Inflammatory Hypothesis of Coronary Artery Disease

Increasing NT-proBNP Isolated as Surrogate for Adverse Outcomes in Heart Failure

TKI Targeted at T790M Lung Cancer Mutations Yields High Rate of Disease Control

Newer P2Y12 Inhibitors in ACS: Significant Reduction in Stent Thrombosis and Mortality

Progress in Development of Reversal Agent for New Oral Anticoagulants

Promising Treatment for Statin-Intolerant Patients with Very High Baseline LDL-C Levels

New Data from IMAgINE 1 Trial Provide Insights on Biologic Use in Pediatric Crohn’s Disease

Interferon-Free Therapies Head for Approval in Hepatitis C on the Basis of Phase 3 Data

Phase 3 Study Validates New Biologic With Gut-Specific Directed Activity